Birch Pollen Allergy - Pipeline Review, H2 2017 Market Report; Launched via MarketResearchReports.com

Birch Pollen Allergy - Pipeline Review, H2 2017, provides an overview of the Birch Pollen Allergy (Immunology) pipeline landscape.

Birch pollen allergy is a reaction which occurs soon after exposure to pollen of birch trees. Signs and symptoms include skin reactions, such as hives, redness or swelling, itching or tingling in or around the mouth and throat, digestive problems, such as diarrhea, stomach cramps, nausea or vomiting, tightening of the throat, shortness of breath or wheezing and runny nose. Predisposing factors include age, family history and other allergies. Treatment includes drugs belonging to class of antihistamines.

Report Highlights

Birch Pollen Allergy - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Birch Pollen Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Birch Pollen Allergy (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Birch Pollen Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 2, 2, 1 and 1 respectively.

Birch Pollen Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Birch Pollen Allergy (Immunology).
• The pipeline guide reviews pipeline therapeutics for Birch Pollen Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Birch Pollen Allergy (Immunology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Birch Pollen Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Birch Pollen Allergy (Immunology)

Reasons to buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Birch Pollen Allergy (Immunology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Birch Pollen Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Spanning over 40 pages “Birch Pollen Allergy - Pipeline Review, H2 2017” report covers Introduction, Report Coverage, Birch Pollen Allergy - Overview, Birch Pollen Allergy - Therapeutics Development, Birch Pollen Allergy - Therapeutics Assessment, Birch Pollen Allergy - Companies Involved in Therapeutics Development, Birch Pollen Allergy - Drug Profiles, Birch Pollen Allergy - Dormant Projects, Appendix. This report Covered Companies - ALK-Abello A/S, Allergy Therapeutics Plc, Anergis SA, Biomay AG, HAL Allergy BV, Laboratorios LETI SL.

Please visit this link for more details: http://mrr.cm/Uqs

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare

Related Reports;

Ventilator Associated Pneumonia (VAP) - Pipeline Review, H2 2017 - Visit at - http://mrr.cm/Uqe

Onychomycosis (Tinea Unguium) - Pipeline Review, H2 2017 - Visit at - http://mrr.cm/Uqn